Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Gracell Biotechnologies Appoints Accomplished Clinical Leader Dr. Wendy Li as Chief Medical Officer 2022-08-01 20:00
Gracell Biotechnologies to Participate in BTIG 2022 Biotechnology Conference 2022-07-26 20:30
Gracell Biotechnologies Appoints Veteran BioPharma Executive Dr. Samuel Zhang as Chief Business Officer 2022-07-19 20:00
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences 2022-06-14 20:00
Gracell Biotechnologies Schedules Clinical Update Call After EHA2022 2022-06-03 23:00
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences 2022-05-19 22:39
Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-targeting CAR-T GC012F in RRMM and B-NHL and CD19/CD7 Dual-directed Allogeneic CAR-T GC502 in B-ALL at EHA2022 Congress 2022-05-12 22:01
Gracell Biotechnologies Announces Details of Oral Abstract Presentation at 2022 ASCO Annual Meeting 2022-04-28 22:30
Gracell Biotechnologies' Abstract on GC012F, a BCMA/CD19 Dual-targeting CAR-T Cell Therapy, Accepted for Presentation at 2022 ASCO Annual Meeting 2022-04-14 20:30
Gracell Biotechnologies to Present Data at AACR Annual Meeting 2022 Showcasing Early First-in-Human Results for GC502 in r/r B-ALL 2022-04-09 04:00
Gracell Biotechnologies Announces Details of Poster Presentation at AACR Annual Meeting 2022 2022-03-09 05:30
Gracell Biotechnologies Announces Multiple Advancements of TruUCAR Allogeneic CAR-T Platform 2022-02-22 20:30
Gracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma 2022-02-17 21:30
Gracell Biotechnologies Unveils Innovation Center in U.S. 2022-01-12 21:00
Gracell Biotechnologies Selected for Addition to NASDAQ Biotechnology Index 2021-12-16 21:00
Gracell Biotechnologies Announces Senior Management Team Share Purchase Plan 2021-11-23 22:00
Gracell Biotechnologies Granted FDA Orphan Drug Designation for FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy Candidate GC012F for the Treatment of Multiple Myeloma 2021-11-19 19:00
Gracell Biotechnologies to Present Preclinical Results of TruUCAR-enabled CD19/CD7 Dual-Directed Allogeneic CAR-T Cell Therapy (GC502) for B-Cell Malignancies at the 63rd ASH Annual Meeting 2021-11-04 21:05
Gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell Therapies Targeting Claudin 18.2 in Solid Tumors 2021-08-16 20:00
Gracell Biotechnologies Hosting Key Opinion Leader Webinar on High Risk Multiple Myeloma, Treatment Challenges and Dual-Targeting CAR-T with Overnight Manufacturing - a Novel Approach for Treatment of Multiple Myeloma 2021-05-26 21:00
1 2 3